Jennison Associates
ZBIO icon

Jennison Associates’s Zenas BioPharma ZBIO Stock Holding History

Jennison Associates’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.97M Buy
314,049
+64,049
+26% +$1.27M ﹤0.01% 410
2026
Q1 		$4.89M Buy
+250,000
New +$5.61M ﹤0.01% 418

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Jennison Associates's ZBIO Position: Q2 2026 in Review

Jennison Associates increased its Zenas BioPharma (ZBIO) stake by 26% in Q2 2026, buying an estimated $1.27M and bringing the position to 314,049 shares worth $7.97M. The position accounts for ﹤0.01% of the portfolio, ranked #410.

Jennison Associates first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Jennison Associates held 314,049 shares of Zenas BioPharma worth $7.97M as of Q2 2026.
  • Jennison Associates bought 64,049 Zenas BioPharma shares in Q2 2026, an estimated $1.27M.
  • Zenas BioPharma made up ﹤0.01% of Jennison Associates's portfolio in Q2 2026, its #410 holding.
  • Jennison Associates first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.